Williams has joined Teva UK in the role of comms manager as the company steps up the PR activity behind both its corporate brand and the products it supplies.
Explaining his appointment, Williams said: 'Teva is not content to be (just) another generics manufacturer. Generics is a price-led market but it doesn't have to be a commodity market.'
The generics industry has boomed in the past few years as top-selling drug brands have lost patent protection.
Teva UK last year launched neuropathic pain relief product Gabapentin, the generic equivalent of Pfizer's Neurontin, and earlier this month launched osteoporosis treatment Alendronic Acid.
Teva's parent firm is based in Israel and employs almost 14,000 staff globally; its operations are mainly in Israel and North America.
It has around 400 staff in the UK, where it was known as APS/Berk until a rebrand last December, and claims the widest product range of all generics manufacturers.
It produces generic products in all major therapeutic areas in various dosage forms, such as tablets, creams, ointments and injectables.
Williams reports to marketing director Kim Inness and is based at Teva UK's headquarters in Leeds.
At FTSE 100 support services group Capita, Williams was marketing and comms manager and worked on issues such as the firm's involvement in London's congestion charge scheme and work with the Department for Education and Skills.
Prior to Capita, Williams spent 11 years at Severn Trent. He joined as exhibitions and publications offer and left as marcoms manager.